Skip to Content


Treatment for Insomnia

Neurocrine Announces Submission of New Drug Application for Indiplon Tablets

Promising New Treatment Option Shown to Help Patients Get a Full Night's Sleep

SAN DIEGO, May 26, 2005 -- Neurocrine Biosciences, Inc. announced that the company has completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for indiplon tablets for the treatment of insomnia in both adult and elderly patients. The NDA for indiplon capsules was submitted to the FDA in April of 2005. These filings are based on clinical data supporting that both indiplon capsules and tablets show significant improvement in all sleep onset, sleep maintenance and sleep quality parameters.

"The indiplon NDA submissions are supported by data from one of the most comprehensive clinical trial programs conducted in insomnia which showcased the consistency with which indiplon helps patients address sleep onset and sleep maintenance problems while improving overall sleep quality," said Gary A. Lyons, President and CEO of Neurocrine Biosciences. "We believe that the flexibility of indiplon in treating the individual sleep needs of patients, coupled with the demonstrated long-term safety, make it an important advancement in the treatment of insomnia."

The indiplon NDA filings contain data from 72 clinical trials and include a comprehensive safety and efficacy evaluation in more than 7,500 subjects. Clinical trial results have shown that indiplon capsules and tablets help patients consistently fall asleep faster, increase the amount of time they sleep during the night, decrease number of nighttime awakenings and improve overall sleep quality over the course of short or long-term treatment without evidence of tolerance when administered nightly for up to three months or withdrawal upon discontinuation of nightly dosing -- complications often seen with extended use of older-generation sleep medications.

About Indiplon
Indiplon is a unique, non-narcotic, non-benzodiazapine agent that acts on a specific site of the GABA-A receptor. Indiplon has been shown to bind selectively to the specific subtype of GABA-A receptors within the brain believed to be responsible for promoting sleep. Indiplon was developed to address different types of sleep problems. Indiplon was licensed from DOV Pharmaceutical in 1998. Upon approval, indiplon will be copromoted in the US with Pfizer.

Insomnia is a prevalent condition in the United States. According to the National Sleep Foundation's (NSF) Sleep in America Poll 2005 approximately half of America's adults report that they experienced at least one symptom of insomnia a few nights a week or more in the past year. Sleep loss has been found to impair the ability to perform tasks involving memory, learning, and logical reasoning, yet few people understand the importance of sufficient sleep.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, and autoimmunity.
For more information, please visit Neurocrine Biosciences, Inc..

Posted: May 2005

Related Articles

Indiplon (NBI-34060) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.